UCB China Signs Strategic Cooperation Agreement with TEDA

Recently, TEDA Administrative Commission and UCB China officially signed a strategic cooperation agreement, marking the beginning of a new era of innovative collaboration in exploring the biopharmaceutical industry. UCB is a globally leading innovative biopharmaceutical company established in Belgium in 1928. The company focuses on developing innovative drugs and therapies for severe diseases of the nervous and immune systems. Following the signing, UCB will leverage its expertise in the innovative research and development of drugs in the fields of the nervous system, immune system, and rare diseases. The agreement aims to introduce advanced R&D technologies and other innovative collaboration patterns in TEDA, as well as promoting its establishment and growth here.

Dr. Alexandre Moreau, the President of UCB China, expressed confidence in the Chinese market and the Tianjin market. He noted that TEDA’s vision of supporting the industry aligns closely with the development needs of UCB and this agreement lays a solid foundation for future cooperation between the two parties.